Related Experiment Videos

The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon

J Brettschneider1, D Ecker, A Bitsch

  • 1Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.

Journal of Neuroimmunology
|November 26, 2002
PubMed

Insights

Soluble CD14 (sCD14), a marker of macrophage activity, was elevated in multiple sclerosis (MS) patients. Interferon beta (IFNB) therapy increased sCD14 levels in primary progressive MS, suggesting sCD14 may indicate treatment response.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Multiple Sclerosis Pathophysiology

Background:

  • Soluble CD14 (sCD14) is a marker of macrophage activation.
  • Elevated sCD14 levels are implicated in various inflammatory conditions.
  • Understanding macrophage activity markers in multiple sclerosis (MS) is crucial for treatment evaluation.

Purpose of the Study:

  • To investigate sCD14 levels in patients with primary progressive MS (PPMS) and relapsing-remitting MS (RRMS).
  • To assess the impact of interferon beta (IFNB) therapy on sCD14 levels in PPMS patients.

Main Methods:

  • Plasma sCD14 levels were measured in 17 PPMS patients and 20 RRMS patients.
  • sCD14 levels in PPMS patients were analyzed before and after IFNB treatment.
  • Comparison with healthy controls was performed.

Main Results:

  • Both PPMS and RRMS patients exhibited significantly elevated sCD14 levels compared to healthy controls.
  • In PPMS patients, sCD14 levels significantly increased within the first 3 months of IFNB therapy.
  • Following the initial increase, sCD14 levels slightly decreased but remained elevated compared to pre-treatment levels.

Conclusions:

  • Elevated sCD14 levels are present in both PPMS and RRMS.
  • sCD14 levels show a dynamic change during IFNB therapy in PPMS.
  • Elevated sCD14 may serve as a valuable biomarker for assessing the biological response to IFNB therapy in MS.

Related Concept Videos